Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Cloud Pharmaceuticals Inc.
DescriptionJanus kinase-2 (JAK-2) inhibitor derivative
Molecular Target Janus kinase-2 (JAK-2)
Mechanism of ActionJanus kinase-2 (JAK-2) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationMyeloproliferative disorder
Indication DetailsTreat myelofibrosis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today